Form 8-K · Current report
Cintas 8-K, filed Oct 6, 2026
- Filed
- CIK
- 0000723254
- Accession no.
- 0000950103-26-015293
Summary
Cintas and UniFirst have each certified substantial compliance with the U.S. Federal Trade Commission's Second Request and completed their response to the Canadian Competition Bureau's Supplementary Information Request in connection with their pending merger, and entered a timing agreement with the FTC barring them from closing before December 11, 2026 unless the FTC gives written notice it has closed its investigation. Cintas said it continues to expect the merger to close before the end of calendar year 2026, subject to customary closing conditions.
Key points
- The merger agreement, dated March 10, 2026, calls for a two-step merger in which UniFirst becomes a wholly owned subsidiary of Cintas.
- Each company received the FTC's Second Request on June 11, 2026 and certified substantial compliance on October 2, 2026.
- Cintas and UniFirst received the Canadian Competition Bureau's Supplementary Information Request on July 2, 2026 and certified completion of their response on September 29, 2026.
- Closing remains subject to conditions including expiration or termination of the applicable Hart-Scott-Rodino waiting period.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
From the filing
Item 8.01 Other Events. As previously disclosed, on March 10, 2026, Cintas Corporation, a Washington corporation (“Cintas”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with (i) UniFirst Corporation, a Massachusetts corporation (“UniFirst”), (ii) Bruin Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Cintas (“Merger Sub Inc.”), and (iii) Bruin Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Cintas (“Merger Sub LLC”). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.